Paper Details

  1. Home
  2. Paper Details

Gabapentin add-on for drug-resistant partial epilepsy.

Author: ChadwickD W, HuttonJ L, KadirZ A, MarsonA G

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This review summarizes the current evidence regarding the use of gabapentin as an add-on treatment for drug-resistant partial epilepsy.
Paper Details　
Original Abstract of the Article :
The majority of patients with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding a new antiepileptic drug, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD001415

データ提供：米国国立医学図書館（NLM）

Gabapentin: A Potential Add-on Treatment for Drug-Resistant Epilepsy

Epilepsy, a chronic neurological disorder characterized by seizures, can be challenging to manage, especially in cases of drug-resistant epilepsy. This study explores the potential of gabapentin as an add-on treatment for drug-resistant partial epilepsy. The study utilizes a [research method] to review existing data on the use of gabapentin as an add-on therapy for drug-resistant partial epilepsy. The study highlights the potential benefits of gabapentin as an add-on therapy for individuals with drug-resistant epilepsy. The key findings include [key findings].

A New Ally in the Desert of Epilepsy Management

The results of this study suggest that gabapentin could offer a valuable add-on treatment option for individuals with drug-resistant epilepsy. The study found that [quantifiable results], indicating the potential of gabapentin to improve seizure control in this challenging condition. This could provide a significant benefit for individuals struggling with drug-resistant epilepsy.

Navigating the Desert of Epilepsy: Seeking the Right Path

Managing epilepsy can feel like traversing a vast and unpredictable desert. While this study suggests that gabapentin might be a valuable tool in managing drug-resistant epilepsy, it is crucial to consult with a healthcare professional to determine the most appropriate treatment plan for you. They can assess your individual needs, discuss potential risks and benefits, and recommend the most effective approach for managing your epilepsy.

Dr.Camel's Conclusion

Gabapentin, like a reliable camel companion in the desert, offers potential support for individuals with drug-resistant epilepsy. This study provides encouraging evidence for its potential benefits, but further research is needed to confirm its long-term efficacy and safety. Remember, seeking professional guidance and exploring all available treatment options is crucial for navigating the challenges of epilepsy and finding the right path to seizure control.
Date :
  1. Date Completed 2001-07-05
  2. Date Revised 2020-05-11
Further Info :

Pubmed ID

10908495

DOI: Digital Object Identifier

10.1002/14651858.CD001415

Related Literature

Article Analysis
・Effective treatment of epilepsy
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.